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838-1 National Patterns of Spironolactone Prescription for 
Older Patients With Heart Failure and Left Ventricular 
Systolic Dysfunction Before and After RALES
Frederick A. Masoudi, Cary P. Gross, Yongfei Wang, Edward P. Havranek, Saif S. 
Rathore, JoAnne Micale Foody, Harlan M. Krumholz, Denver Health Medical Center, 
Denver, CO, Yale University School of Medicine, New Haven, CT
Background: In the RALES trial, published in September 1999, spironolactone improved
survival in selected patients with heart failure and left ventricular systolic dysfunction
(LVSD). Because of the risk of hyperkalemia, however, guidelines advise against use in
patients with K>5.0 mmol/l or creatinine>2.5 mg/dl.
Methods: Using data from the Centers for Medicare and Medicaid Services’ National
Heart Care Project, we studied Medicare patients > 65 years old with LVSD discharged
after hospitalization for heart failure in two time periods: 4/1998—3/1999 (before RALES
n= 9,758) or 7/2000—6/2001 (after RALES, n=9,468). We assessed changes in rates of
spironolactone prescription at discharge between periods in all patients and in strata
according to potassium and creatinine levels.
Results: Spironolactone prescriptions increased more than seven-fold between the two
samples (Table).Although prescription rates were higher in patients with creatinine <2.5
mg/dl, proportions of patients receiving spironolactone increased significantly in both cre-
atinine strata. Rates were similar in patients with normal potassium and those with rela-
tive hyperkalemia.
Conclusions: Spironolactone use nationwide increased markedly after the publication of
the RALES trial among older patients hospitalized with heart failure and LVSD. This use,
however, has extended to patients who are at a high risk for adverse outcomes. Current
patterns of practice may pose hazards to the safety of some patients.
10:45 a.m.
838-2 Rofecoxib Increases Cardiovascular Events in Arthritis 
Patients but Celecoxib and Nonspecific Nonsteroidal 
Anti-Inflammatory Drugs Do Not: Results From a Large 
New England Health Care Claims Database
Andrew Whelton, William M. Spalding, William B. White, Matthew J. Reeves, Sandy S. 
Suh, John G. Fort, Universal Clinical Research Center Inc, Hunt Valley, MD
Background: Treatment with cyclooxygenase-2 (COX-2) specific inhibitors may lead to
adverse cardiovascular (CV) events.
Objective: Determine relative risk (RR) of acute MI (AMI) or stroke associated with the
COX-2 specific inhibitors celecoxib and rofecoxib, and nonspecific NSAIDs in treated
hypertensive patients with osteoarthritis (OA) and/or rheumatoid arthritis (RA) in a large
New England healthcare claims database.
Methods: Population based retrospective analysis of >3 million patients aged >18 years
enrolled in a private medical insurance plan in the New England region of the US, from
January 1, 1999 - June 30, 2001. Enrollment, medical claims data and pharmacy claim
records were computer linked. NSAID and COX-2 specific users were identified using
NDC codes. Outcomes of interest were identified by ICD-9-CM codes 410-414 (AMI) or
430-436 (stroke). Sub-group analysis included prostaglandin-mediated antihypertensives
(ACEI, ARB, β-blocker). The incidence of CV events was estimated using Cox propor-
tional hazard time-to-event models adjusted for CV risk factors.
Results: RR for CV events with rofecoxib vs nonusers of NSAIDs was 2.45. No differ-
ences in RR were noted for celecoxib vs NSAIDS (p = 0.40) or nonusers (p = 0.06) and
NSAIDs vs non-users (p = 0.59). 
Conclusions: Rofecoxib significantly increases risk of AMI or stroke in treated 
hypertensive patients with OA or RA compared with nonusers. Patients receiving 
celecoxib, nonspecific NSAIDs, ACEI, ARB or β-blockers are at no enhanced risk.
11:00 a.m.
838-3 Safety and Efficacy of Glycoprotein IIb/IIIa Receptor 
Blockers in Patients With Chronic Renal Insufficiency 
Undergoing Contemporary Percutaneous Coronary 
Intervention
Mauro Moscucci, Dean E. Smith, Arthur Riba, Raj Goswami, Anthony DeFranco, Sanjaya 
Khanal, Michael O'Donnell, David Share, Kim A. Eagle, For the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium, University of Michigan, Ann Arbor, MI
Background: Chronic renal insufficiency (CRI) has been an exclusion criteria in clinical
trials of glycoprotein (Gp) IIb/IIIa receptor blockers. The objective of our study was to
evaluate safety and efficacy of GpIIb/IIIa blockers in patients with CRI undergoing con-
temporary percutaneous coronary intervention (PCI).
Methods: Data on 48,851 PCIs were collected in a regional consortium between 7/1997
and 5/2003. CRI was defined as baseline creatinine > 2 mg/dl. Patients with CRI receiv-
ing GpIIb/IIIa blockers (n=880) were compared with patients who did not (n=793). End-
points analyzed included hospital death, bleeding, and a composite major adverse
cardiac event (MACE) of death, emergency CABG, stroke and myocardial infarction (MI).
Bleeding was defined as any blood transfusion (tx) regardless the number of units.
Results: Patients receiving GpIIb/IIIa blockers were more likely to undergo emergency
PCI, and to undergo PCI for acute MI, shock and complex coronary stenosis (Table).
After adjustment for comorbidities, GpIIb/IIIa blockers were associated with a 36% risk
reduction of MACE (adjusted OR 0.64, 95% CI 0.43-0.96, p=0.03). No significant effect
was observed on mortality (adjusted OR 0.99, 95% CI 0.60-1.62, p=0.9) and tx (adjusted
OR 1.13, 95% CI 0.84-1.51, p=0.4).
Conclusions: PCI in patients with CRI continues to be associated with high in-hospital
morbidity and mortality. GpIIb/IIIa blockers in this patient population result in a significant
reduction in MACE without an increase in bleeding. 
11:15 a.m.
838-4 National Evaluation of Long-Term Adherence to Beta-
Blocker Therapy After Acute Myocardial Infarction in 
Patients With Commercial Health Insurance
Judith M. Kramer, Donald Fetterolf, John P. Charde, Richard Snyder, Daniel Checkman, 
Elizabeth DeLong, Nancy Allen LaPointe, Barbara Hoffman, Rhonda L. Arrington, Eric 
Peterson, Duke Clinical Research Institute, Durham, NC
Background: Despite a Class IA guideline recommendation for chronic use of beta-
blockers after acute myocardial infarction (MI), few studies have evaluated long-term
adherence to beta-blocker therapy after MI in a population with commercial insurance.
Methods: Using pharmacy claims data, nine health plans that are members of the Coun-
cil for Affordable Quality Healthcare (CAQH) performed a retrospective analysis of one-
year survivors of MI to measure cumulative population adherence to beta-blockers for 3,
6, 9, and 12 months after MI. Patients with MI in year 2000 were identified; beta-blocker
claims were determined for the subsequent 12 months. Health plans used common tech-
Rate
before RALES (n)
Rate
after RALES (n)
p
Total 3.0% (9,758) 21.3% (9,468) <0.0001
Creatinine
<2.5 mg/dL
3.1% (8,933) 22.0% (8,592) <0.0001
Creatinine
>2.5 mg/dL
1.9% (825) 14.1% (876) <0.0001
K <5.0 mmol/dL 3.0% (9,267) 21.2% (8,938) <0.0001
K >5.0 mmol/dL 2.7% (491) 22.8% (530) <0.0001
Treated Hypertensive 
Patients*
Non-users
N=1798
Celecoxib
N=1288
Rofecoxib
N=841
NSAIDs
N=1594
Years of exposure 3612.7 982.1 453.6 938.1
Relative Risk 1.00
(Reference)
1.35
(0.98, 1.86)
(p = 0.06)
2.45
(1.71, 3.51)
(p < 0.0001)
1.11
(0.74, 1.67)
(p = 0.59)
Sub-Group
ACE-I, ARB, β-Beta 
Blockersblockers
1.00
(Reference)
1.30
(0.90, 1.88)
(p = 0.17)
2.18
(1.41, 3.36)
(p = 0.0004)
0.91
(0.55, 1.50)
(p = 0.72)
* Adjusted for CV risk factors.
Variable (%) GpIIb/IIIa
yes (880)
GpIIb/IIIa
no (793)
p - value
Age 66.6 67.2 0.33
Female sex 33.6 41.1 0.002
PVD % 42.7 44.4 0.49
Type C Lesion 28.6 19.2 <0.001
Visible Thrombus 25.6 15.0 <0.001
Emergency Procedure 20.2 14.5 0.002
Acute MI 17.3 11.7 0.001
Cardiac Arrest 6.1 4.8 0.23
Cardiogenic shock 6.7 5.8 0.45
Outcomes
In-hospital mortality 6.9 6.4 0.68
MACE 9.2 10.7 0.30
Transfusion 18.6 17.2 0.47
